Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Irene M. Ghobrial"'
Autor:
Justin Cha, Cody J. Boehner, Nikhil C. Munshi, Romanos Sklavenitis-Pistofidis, Kwee Yong, Chip Stewart, Karma Salem, Eliezer M. Van Allen, Jihye Park, Yu-Tzu Tai, Andrew Dunford, Shankara Anand, Lorenzo Trippa, Amaro Taylor-Weiner, Jacob P. Laubach, Mark Bustoros, Benny Zhitomirsky, Robert A. Redd, Selina J Chavda, Irene M. Ghobrial, Shaji Kumar, Paul G. Richardson, Kenneth C. Anderson, François Aguet, Tarek H. Mouhieddine, P. Leif Bergsagel, Gad Getz, Mahshid Rahmat, Tineke Casneuf, Meletios A. Dimopoulos, Liudmila Elagina, Carl Jannes Neuse, Salomon Manier, Elizabeth A. Morgan, Ignaty Leshchiner, Efstathis Kastritis
Publikováno v:
J Clin Oncol
PURPOSE Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The disco
Autor:
Irene M. Ghobrial, Oliver Lomas
Publikováno v:
American Society of Clinical Oncology Educational Book. :314-319
Forty years ago this year, smoldering multiple myeloma was defined as a clinical entity that identifies a group of patients with a substantial burden of disease but with a relatively indolent natural history compared with symptomatic disease. Since t
Autor:
Omar Nadeem, Robert Redd, Clifton Craig Mo, Jacob Laubach, Julia Prescott, Amada Metivier, Christine Davie, Meredith Bertoni, Elizabeth Murphy, Brian Sheehan, Kelsey Tague, Hira Shrestha, Rebekah Medina, Alexandra Distaso, Houry Leblebjian, Paul G. Richardson, Irene M. Ghobrial
Publikováno v:
Journal of Clinical Oncology. 40:8040-8040
8040 Background: Early therapeutic intervention with lenalidomide has shown to be effective in delaying progression in patients with high-risk smoldering multiple myeloma (HR-SMM) (Lonial J Clin Oncol 2020). Quadruplet regimen of daratumumab, bortezo
Autor:
Clifton C. Mo, Irene M. Ghobrial, Kenneth C. Anderson, Michelle M Mesa, Areej El-Jawahri, Omar Nadeem, Adam S. Sperling, Jacob P. Laubach, Nikhil C. Munshi, Paul G. Richardson, Emerentia Agyemang, Cynthia C. Harrington, Yael N Shapiro, Andrew Yee, Noopur Raje, Lisette R. Packer, Jill N. Burke, Elizabeth O'Donnell, Andrew R. Branagan
Publikováno v:
Journal of Clinical Oncology. 39:12082-12082
12082 Background: Caregivers of patients with cancer play a critical role in supporting patients when making informed decisions about their medical care. Although MM patients and their caregivers face an incurable illness, data describing caregiver p
Publikováno v:
American Society of Clinical Oncology Educational Book. :548-560
Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by notable interpatient heterogeneity. There have been important advances in therapy and overall survival, but some patients with high-risk features still have poor survival r
Autor:
Romanos Sklavenitis-Pistofidis, Irene M. Ghobrial, Jorge J. Castillo, Steven P. Treon, Mark Bustoros
Publikováno v:
Journal of Clinical Oncology. 37:2701-2702
Autor:
L. Gardner, Amrita Krishnan, Robert L. Schlossman, Jeff Allerton, Jacob P. Laubach, David Irwin, Sagar Lonial, Kathleen Colson, John J. Densmore, Noopur Raje, Peter Sportelli, Jeff Zonder, Enrique Poradosu, Jeff Wolf, Andrzej Jakubowiak, Kenneth C. Anderson, Michael Bar, Paul G. Richardson, Irene M. Ghobrial, Teru Hideshima, Thomas Martin, Nikhil C. Munshi
Publikováno v:
Journal of Clinical Oncology. 29:4243-4249
Purpose Novel agents have improved patient outcome in relapsed or relapsed/refractory multiple myeloma (MM). Preclinical data show that the novel signal transduction modulator, perifosine, enhances the cytotoxicity of dexamethasone and bortezomib. Cl
Autor:
Irene M. Ghobrial, William S. Dalton, Dixie-Lee Esseltine, Amitabha Mazumder, Melissa Alsina, David Avigan, Paul G. Richardson, Robert L. Schlossman, Teru Hideshima, Carol Delaney, Diane Warren, Nikhil C. Munshi, Deborah Doss, Kenneth C. Anderson, Sundar Jagannath, Laura E. Lunde, Rob Knight, Constantine S. Mitsiades, Edie Weller, Mary McKenney
Publikováno v:
Journal of Clinical Oncology. 27:5713-5719
Purpose Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to bortezomib and dexamethasone. This phase I, dose-escalation study (ie, NCT00153933)
Autor:
Irene M. Ghobrial, Jeffrey Matous, Jorge J. Castillo, Patrick Henrick, Joseph Cappuccio, Steven P. Treon, Emily Lai, Aaron M. Caola
Publikováno v:
Journal of Clinical Oncology. 34:8065-8065
8065Background: This follow-up study aimed to update the progression-free survival (PFS) and identify responder subgroups in the phase II trial of Bortezomib and Rituximab in patients with Waldenst...
Autor:
Jacalyn Rosenblatt, Michael Gary Martin, Robert L. Schlossman, Philippe Armand, Kenneth C. Anderson, Stew Kroll, Rebecca Liguori, Craig H. Reynolds, Stacey Chuma, Damian Handisides, J. A. Hedlund, Paul G. Richardson, Noopur Raje, Erica N Boswell, Irene M. Ghobrial, Ira Zackon, Kenneth H. Shain, Andrew Yee, Laura Stampleman, Jacob P. Laubach
Publikováno v:
Journal of Clinical Oncology. 33:8579-8579
8579 Background: The presence of hypoxia in the diseased bone marrow presents a new therapeutic target for multiple myeloma (MM) (Colla, Leukemia 2010). Evofosfamide (EVO; formerly TH-302) is a nov...